Meeder Asset Management Inc. bought a new position in shares of Encompass Health Corporation (NYSE:EHC – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 43,669 shares of the company’s stock, valued at approximately $4,414,000.
A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Encompass Health during the second quarter worth $1,059,762,000. Deutsche Bank AG bought a new position in shares of Encompass Health in the second quarter valued at about $1,285,000. Rice Hall James & Associates LLC bought a new position in shares of Encompass Health in the second quarter valued at about $4,047,000. TimesSquare Capital Management LLC acquired a new stake in shares of Encompass Health during the 2nd quarter worth about $38,221,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Encompass Health during the 2nd quarter worth about $36,000. Institutional investors own 97.25% of the company’s stock.
Insider Buying and Selling at Encompass Health
In other news, EVP John Patrick Darby sold 8,906 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the completion of the transaction, the executive vice president owned 75,041 shares of the company’s stock, valued at approximately $9,451,413.95. The trade was a 10.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.47, for a total value of $21,724,879.56. Following the sale, the chief executive officer owned 267,814 shares of the company’s stock, valued at approximately $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.80% of the stock is owned by corporate insiders.
Encompass Health Trading Up 0.3%
Encompass Health (NYSE:EHC – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the company earned $1.40 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. On average, analysts forecast that Encompass Health Corporation will post 6.08 earnings per share for the current fiscal year.
Encompass Health Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.21 per share. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. The ex-dividend date is Thursday, October 1st. Encompass Health’s dividend payout ratio (DPR) is presently 12.38%.
Analyst Upgrades and Downgrades
EHC has been the topic of a number of research reports. Weiss Ratings upgraded shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday. Barclays upped their target price on Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Truist Financial increased their target price on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, UBS Group lifted their price target on Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $148.71.
View Our Latest Analysis on Encompass Health
About Encompass Health
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Featured Articles
- Five stocks we like better than Encompass Health
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
